MGF (Mechano Growth Factor) vs Myostatin Inhibitor
A side-by-side research comparison of MGF (Mechano Growth Factor) and Myostatin Inhibitor across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | MGF (Mechano Growth Factor) | Myostatin Inhibitor |
|---|---|---|
| Full name | Mechano Growth Factor (IGF-1Ec splice variant) | Myostatin Inhibitor Peptides (Anti-GDF-8) |
| Category | Muscle Growth | Muscle Growth |
| Status | Research compound | Research compound |
| Mechanism | Unique E-domain activates quiescent satellite cells for proliferation. Distinct from IGF-1Ea which drives differentiation. PEGylated form extends short half-life. | Propeptide mimics bind mature myostatin; peptide aptamers block ActRIIB; small antagonists compete for receptor. All prevent myostatin-mediated suppression of muscle growth. |
| Molecular weight | 2,867 Da (synthetic fragment) | 2,000-15,000 Da (varies) |
| Half-life | 5-7 min (native) / 24-48h (PEGylated) | 4-48 hours (design-dependent) |
| Bioavailability | High (local IM) | Variable (SubQ) |
| Typical dose | 100-200 mcg PEG-MGF | 50-500 mcg |
| Frequency | 2-3x per week | 3-7x per week |
| Route | Intramuscular (local) | Subcutaneous |
MGF (Mechano Growth Factor) reported benefits
- Satellite cell activation
- Muscle-specific growth
- Repair response enhancement
- Synergistic with training
- Local hypertrophy
Myostatin Inhibitor reported benefits
- Muscle growth promotion
- Strength increase
- Myostatin blockade
- Muscle wasting treatment potential
- Metabolic improvement
Related comparisons
Research and educational reference only. Not medical advice.